Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on TGTX. TG Therapeutics, Inc.’s share was trading at $50.54 as of June 16th. TGTX’s trailing and forward P/E were 17.59 and 38.76 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
TG Therapeutics, Inc. (TGTX) is a commercial-stage biopharmaceutical company focused on treating multiple sclerosis, positioned within profitable, revenue-generating specialty pharma businesses with durable commercial traction, supported by strong recurring revenue visibility. The company’s lead therapy, BRIUMVI, is an anti-CD20 monoclonal antibody designed to selectively deplete immune cells that drive inflammatory damage in relapsing forms of MS.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Already approved in the United States and available in multiple international markets through partnerships, BRIUMVI is steadily expanding its commercial footprint, with growing adoption among neurologists in both private practice and major academic treatment centers, supporting accelerating prescription growth and gradual switching from legacy therapies in the MS market. A key strength of the asset is its persistence, as patients who initiate therapy tend to remain on treatment, creating a compounding revenue base strengthening visibility over time.
TG Therapeutics is broadening its addressable market through a subcutaneous self-administration formulation allowing patients to receive therapy at home, and a simplified single-infusion regimen in late-stage development, expanding convenience-driven uptake. In a specialty pharma landscape increasingly shaped by payer scrutiny, BRIUMVI’s long-term clinical data demonstrating sustained disease control provides meaningful support in formulary negotiations and reimbursement discussions.
This positions the company favorably as insurers prioritize therapies with durable outcomes and clear cost-effectiveness, amid increasing institutional demand backdrop. At the same time, investor flows are shifting toward commercial-stage biotech companies with visible cash generation and de-risked pipelines, aligning well with TG Therapeutics’ profile.
Recent trading behavior, marked by rising volume and upward price momentum, suggests institutional participation and strengthening conviction, reinforcing a constructive setup for continued execution and potential rerating as adoption deepens today outlook.